Results 51 to 60 of about 1,690 (152)

Genome‐Wide Protein Interaction Analysis in Parasitic Gyrodactylus Flatworms–Fish Hosts System and Drug Target Identification

Advanced Science, Volume 12, Issue 45, December 4, 2025.
Genomic data offer a powerful tool for studying the molecular interactions between parasites and their hosts, but they remain scarce for parasitic monogenean flatworms. This study presents the first high‐quality phased genome assembly for monogeneans (Gyrodactylus kobayashii), and uses it to predict key interacting proteins between monogenean parasite ‐
Dong Zhang, Jie‐Mei Zhao, Chuan‐Yu Xiang, Yi‐Wen Ma, Hong‐Peng Lei, Yu‐Ying Shi, Shun Zhou, Xiaofei Zeng, Jinsong Chen, Fei Liu, Benhe Zeng, Rui Song, Ye Hu, Feng Zhang, Xiang Liu, Wen‐Xiang Li, Gui‐Tang Wang, Ivan Jakovlić   +17 more
wiley   +1 more source

Familial Hypercholesterolemia and Its Current Diagnostics and Treatment Possibilities: A Literature Analysis

Medicina, 2022
Familial hypercholesterolemia (FH) is a common, inherited disorder of cholesterol metabolism. This pathology is usually an autosomal dominant disorder and is caused by inherited mutations in the APOB, LDLR, and PCSK9 genes. Patients can have a homozygous
Kristina Zubielienė, Gintarė Valterytė, Neda Jonaitienė, Diana Žaliaduonytė, Vytautas Zabiela   +4 more
doaj   +1 more source

An improved assay to measure the phospholipid transfer activity of microsomal triglyceride transport protein

Journal of Lipid Research, 2021
Microsomal triglyceride transfer protein (MTP) is essential for the assembly and secretion of apolipoprotein B-containing lipoproteins. MTP transfers diverse lipids such as triacylglycerol (TAG) and phospholipids (PLs) between vesicles in vitro ...
Narasimha Anaganti, Sujith Rajan, M. Mahmood Hussain   +2 more
doaj   +1 more source

Population Pharmacokinetics and Exposure‐Response Modeling for Evinacumab in Children, Adolescents, and Adults With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 11, Page 1823-1834, November 2025.
ABSTRACT Evinacumab, an angiopoietin‐like 3 (ANGPTL3) inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C), independent of low‐density lipoprotein receptor, in patients with homozygous familial hypercholesterolemia (HoFH). A population pharmacokinetic (PK)/pharmacodynamic (PD) model was previously developed to characterize ...
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Yuhuan Wang, Poulabi Banerjee, Robert Pordy, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +8 more
wiley   +1 more source

Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 11, Page 1835-1847, November 2025.
ABSTRACT Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH.
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Katy C. Norman, Richard T. George, Xue‐Qiao Zhao, Robert Pordy, Daniel Garcia, Wendy S. Putnam, Geetha Raghuveer, Brian W. McCrindle, Elena Fornari, Ivo Baric, Shubha Srinivasan, Melissa Diamond, Eliot A. Brinton, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +18 more
wiley   +1 more source

Crystal structure of 9-(4-bromobutyl)-9H-fluorene-9-carboxylic acid

Acta Crystallographica Section E, 2014
The title compound, C18H17BrO2, is a key intermediate in the synthesis of lomitapide mesylate, a microsomal triglyceride transfer protein inhibitor. Its asymmetric unit contains two independent molecules with slightly different conformations; the mean ...
Xu-Yang Zhang, Bing-Ni Liu, Ping-Bao Wang, Deng-Ke Liu   +3 more
doaj   +1 more source

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications

Diabetes, Obesity and Metabolism, Volume 27, Issue S8, Page 34-46, September 2025.
Abstract Lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). Despite robust evidence from epidemiological and genetic studies, Lp(a) remains underrecognised in clinical practice due to challenges in measurement, lack of guideline familiarity ...
Alexander C. Razavi, Harpreet S. Bhatia, Roger S. Blumenthal, Michael D. Shapiro, Anurag Mehta   +4 more
wiley   +1 more source

Use of Potentially Inappropriate Medications Identified by STOPPFrail Among Danish Care Home Residents: A Nationwide Drug Utilisation Study

Basic &Clinical Pharmacology &Toxicology, Volume 137, Issue 2, August 2025.
ABSTRACT Care home residents represent a frail population with limited life expectancy and are often prescribed multiple medications. As therapeutic goals shift in this population, certain treatments may become inappropriate. This study aims to describe potentially inappropriate medication use among Danish care home residents using the Screening Tool ...
Katrine Mose, Carina Lundby, Martin Thomsen Ernst, Jesper Ryg, Anton Pottegård, Lotte Rasmussen   +5 more
wiley   +1 more source

Cost‐Effective Nanosensor Solutions for Ultra‐Sensitive Detection of Metronidazole

Analytical Science Advances, Volume 6, Issue 1, June 2025.
ABSTRACT Metronidazole (MNZ) is a widely used imidazole antibiotic effective against bacterial and protozoal infections, including giardiasis, trichomoniasis, bacterial vaginosis, and antibiotic‐associated colitis. However, prolonged and excessive use of MNZ can lead to serious side effects, such as peripheral neuropathies, toxicity, and optic ...
Ahmad Mobed, Mohammad Darvishi, Vahid Alivirdiloo, Sara Ebrahimi, Mobasher Hajiabbasi, Farhood Ghazi, Hamidreza Hassanzadeh Khanmiri   +6 more
wiley   +1 more source

Depletion of Hepatic SREBP2 Protects Against Hypercholesterolemia and Atherosclerosis through the ANGPTL3‐LPL Axis

Advanced Science, Volume 12, Issue 18, May 15, 2025.
This study reveals a novel crosstalk between hepatic SREBP2‐mediated cholesterol biosynthesis pathway and peripheral lipoprotein lipase‐mediated lipolysis pathway in the regulation of systemic lipid metabolism. Notably, the lipid‐lowering effects of SREBP2 inhibition are independent of a functional LDL receptor, highlighting the potential of acute ...
Yifan Wang, Jia You Sarafina Choe, Yu Shi, Thi Tun Thi, Xiaoyun Cao, Yang Hu, Kai Yan Cheng, Hui Li, Yang Ji, Yan Liu, Matthew Ackers‐Johnson, Roger S.Y. Foo, Yujia Shen, Haojie Yu   +13 more
wiley   +1 more source